Does COVID-19 antibody serology testing correlate with disease severity? An analytical descriptive retrospective study

AIM: To find out if there is any correlation between COVID-19 antibody serological testing and symptom severity. METHODS: This study is a case series of 44 consecutive patients confirmed with COVID-19 who are divided into a group of 23 patients with mild disease and a group of 21 patients with severe disease. All 44 samples were confirmed positive SARS-CoV-2. Subsequent recombinant SARS-CoV-2 S1/S2 IgG test was performed for all patients and all patients developed neutralizing antibodies with altered range. MAIN OUTCOMES: IgG level and its correlation with disease severity, demographic data, underlying comorbidities, clinical presentation, and treatment comparison between mild and severe disease groups. RESULTS: Quantitative SARS COV-2 IgG was significantly higher in moderate and severe disease groups compared with those in the mild disease group. COVID-19 infection was more prevalent in male, Saudi nationals and smokers with comorbidities and higher inflammatory markers are more in the severe group than in the mild group which necessitates more management options to be taken for severe group patients. CONCLUSION: IgG antibody level was higher in the severe disease group. Also, the study showed significant differences between the mild and severe disease groups in terms of demographic, clinical, and management variables.